Home > Blog > Apples to apples playing the comparability game in biotherapeutics development

Apples to Apples: Playing the Comparability Game in Biotherapeutics Development

Regulatory Consulting

Comparability studies are a significant issue for those working in biotherapeutics development, as undetected product changes are considered high risk.

Listen to the full episode on Veristat’s Advancing Revolutionary Therapies Podcast to get important insights and recommendations on how to successfully plan your clinical and CMC manufacturing development plans to reduce your regulatory risk along the way.

Learning Points

  • The importance of comparability studies for biologics
  • Key aspects of a comparability assessment
  • How to determine analytical and stability parameters when measuring comparability
  • Conditions for evaluating stability studies

LISTEN TO PODCAST

 

Meet Veristat. Learn More.

1 min read

Connect with Veristat at OCT East Coast

Apr 30, 2026  Veristat Events

May 12-13, 2026 – New Brunswick, NJ

⚛️ Where Clinical Operations Meet Real-World Execution

Veristat is pleased to...

1 min read

Meet Veristat at the ASGCT Annual Meeting

Apr 30, 2026  Veristat Events

May 11-15, 2026 – Boston, MA

🔬  Where Cell and Gene Therapy Moves Forward

Veristat is pleased to attend the ASGCT...